Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy.
Nils Kroeger(Universitätsmedizin Greifswald), Daniel Yick Chin Heng(University of Calgary), Min‐Han Tan(National Cancer Centre Singapore), Sumanta K. Pal(City of Hope), Ulka N. Vaishamayan(Wayne State University), Aristotelis Bamias(National and Kapodistrian University of Athens), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Scott North, Sun Young Rha(Yonsei University), Jennifer J. Knox(National Cancer Center), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Sandy Srinivas(Stanford University), Mary J. MacKenzie(Cancer Care Ontario), Neeraj Agarwal(University of Utah), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k